Navesta Pharmaceuticals has opened a $9.1 million sterile manufacturing facility in Sri Lanka that is compliant with European Good Manufacturing Practices.
The 40,000-square-foot plant is equipped with the country’s first EU-GMP compliant A and B grade microbiology lab. The plant is expected to meet local demand for penicillin products, the company said.
The facility has a capacity to produce 50 million vials and is expected to increase production capacity threefold in the next few years.
“Navesta’s ultimate aim is to provide a reliable, vertically integrated local supply chain which will provide accessibility of high-quality pharmaceuticals for our citizens,” Sanjaya Jayaratne, Navesta’s chairman, said in a statement. “All our efforts surround the idea that we as a company have a social responsibility to this generation and the next in providing our citizens better opportunities of a livelihood through our continual industry development, reinvestment in the communities, and empowerment of our employees to carry this vision forward for Sri Lanka.”
About 100 new jobs were created with the opening of the plant, the company said.